[
    [
        {
            "time": "2018-10-29",
            "original_text": "Health Care Sector Update for 10/29/2018: MLNT,BDSI,TXMD,PFE,NVS",
            "features": {
                "keywords": [
                    "health care",
                    "sector update",
                    "PFE",
                    "NVS"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Pre-Market Earnings Report for October 30, 2018: PFE, MA, KO, GE, AMT, AET, AGN, HCA, ECL, CTSH, BP, LYB",
            "features": {
                "keywords": [
                    "earnings report",
                    "pre-market",
                    "PFE",
                    "MA",
                    "KO"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "various"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Stocks Attempt Rally, IBM Buys Red Hat, & Q3 Earnings Season Stays Hot",
            "features": {
                "keywords": [
                    "rally",
                    "IBM",
                    "Red Hat",
                    "Q3 earnings"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Pfizer earnings: Looking toward an ambitious 2022 agenda",
            "features": {
                "keywords": [
                    "Pfizer",
                    "earnings",
                    "2022 agenda"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Pfizer's Q3 Earnings Preview",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Q3 earnings",
                    "preview"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Novartis, Pfizer join forces on potentially lucrative fatty liver disease",
            "features": {
                "keywords": [
                    "Novartis",
                    "Pfizer",
                    "liver disease"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Novartis",
                    "NASH",
                    "clinical development"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-10-30",
            "original_text": "European Shares To Open On Cautious Note Amid China Growth Woes",
            "features": {
                "keywords": [
                    "European shares",
                    "cautious note",
                    "China growth"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "global markets"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]